• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

腺癌组织学转化为小细胞肺癌作为一种罕见的表皮生长因子受体酪氨酸激酶抑制剂耐药机制：1例报告并文献复习

Histological transformation of adenocarcinoma to small cell carcinoma lung as a rare mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors: Report of a case with review of literature.

作者信息

Hui Monalisa, Uppin Shantveer G, Stalin Bala Joseph, Sadashivudu G

机构信息

Department of Pathology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India.

Department of Medical Oncology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India.

出版信息

Lung India. 2018 Mar-Apr;35(2):160-163. doi: 10.4103/lungindia.lungindia_347_17.

DOI:10.4103/lungindia.lungindia_347_17
PMID:29487254
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5846268/
Abstract

A subset of non-small cell lung carcinoma (NSCC) harbor active mutations of epidermal growth factor receptor (EGFR). In these, EGFR tyrosine kinase inhibitors (EGFR-TKIs) are recommended as the first-line treatment. Though drug resistance is inevitable, histological transformation to small cell lung carcinoma (SCLC) is a rare mechanism for acquired resistance. Here we report one such rare case of histological transformation of pulmonary adenocarcinoma to small cell lung carcinoma in 46 year old male treated with Gefitinib.

摘要

一部分非小细胞肺癌（NSCC）存在表皮生长因子受体（EGFR）的活性突变。对于这些患者，推荐将表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）作为一线治疗药物。尽管耐药不可避免，但组织学转化为小细胞肺癌（SCLC）是获得性耐药的一种罕见机制。在此，我们报告一例46岁男性肺腺癌组织学转化为小细胞肺癌的罕见病例，该患者接受了吉非替尼治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b90/5846268/19111d564166/LI-35-160-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b90/5846268/c146ef47581a/LI-35-160-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b90/5846268/a8ddf45a733f/LI-35-160-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b90/5846268/19111d564166/LI-35-160-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b90/5846268/c146ef47581a/LI-35-160-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b90/5846268/a8ddf45a733f/LI-35-160-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b90/5846268/19111d564166/LI-35-160-g003.jpg

相似文献

1
Histological transformation of adenocarcinoma to small cell carcinoma lung as a rare mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors: Report of a case with review of literature.腺癌组织学转化为小细胞肺癌作为一种罕见的表皮生长因子受体酪氨酸激酶抑制剂耐药机制：1例报告并文献复习
Lung India. 2018 Mar-Apr;35(2):160-163. doi: 10.4103/lungindia.lungindia_347_17.
2
Resistance to epithelial growth factor receptor tyrosine kinase inhibitors in a patient with transformation from lung adenocarcinoma to small cell lung cancer: A case report.1例肺腺癌转化为小细胞肺癌患者对表皮生长因子受体酪氨酸激酶抑制剂耐药：病例报告
Oncol Lett. 2017 Jul;14(1):593-598. doi: 10.3892/ol.2017.6229. Epub 2017 May 23.
3
Transformation of mutated lung adenocarcinoma to small-cell carcinoma long after the cessation of tyrosine kinase inhibitor treatment: A case series and literature review.酪氨酸激酶抑制剂治疗停止很久后，突变型肺腺癌转化为小细胞癌：病例系列及文献综述
Respir Med Case Rep. 2024 Jun 21;51:102076. doi: 10.1016/j.rmcr.2024.102076. eCollection 2024.
4
Advanced Lung Adenocarcinoma with EGFR 19-del Mutation Transformed into SCC after EGFR-tyrosine Kinase inhibitors Treatment: A Case report.表皮生长因子受体19号外显子缺失突变的晚期肺腺癌在表皮生长因子受体酪氨酸激酶抑制剂治疗后转化为鳞状细胞癌：一例报告
World J Clin Cases. 2024 Jul 16;12(20):4405-4411. doi: 10.12998/wjcc.v12.i20.4405.
5
Transformation From Adenocarcinoma to Pleomorphic Carcinoma as an Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.腺癌向多形性癌的转化作为对表皮生长因子受体酪氨酸激酶抑制剂的获得性耐药。
J Med Cases. 2021 Aug;12(8):310-314. doi: 10.14740/jmc3710. Epub 2021 Jul 3.
6
Histological transformation from non-small cell to small cell lung carcinoma after treatment with epidermal growth factor receptor-tyrosine kinase inhibitor.表皮生长因子受体酪氨酸激酶抑制剂治疗后发生的非小细胞向小细胞肺癌的组织学转化。
Thorac Cancer. 2015 Nov;6(6):800-4. doi: 10.1111/1759-7714.12217. Epub 2014 Dec 29.
7
Case report: small cell transformation and metastasis to the breast in a patient with lung adenocarcinoma following maintenance treatment with epidermal growth factor receptor tyrosine kinase inhibitors.病例报告：一名肺腺癌患者在接受表皮生长因子受体酪氨酸激酶抑制剂维持治疗后发生小细胞转化并转移至乳腺。
BMC Cancer. 2016 Aug 3;16:593. doi: 10.1186/s12885-016-2623-4.
8
[Advances in the Transformation to Small Cell Lung Cancer from Non-small Cell Lung Cancer Following Acquired Drug-resistance to EGFR Tyrosine Kinase Inhibitors].[表皮生长因子受体酪氨酸激酶抑制剂获得性耐药后非小细胞肺癌向小细胞肺癌转化的研究进展]
Zhongguo Fei Ai Za Zhi. 2017 Oct 20;20(10):720-726. doi: 10.3779/j.issn.1009-3419.2017.10.10.
9
Transformation to large cell neuroendocrine carcinoma as acquired resistance mechanism of EGFR tyrosine kinase inhibitor.转化为大细胞神经内分泌癌作为 EGFR 酪氨酸激酶抑制剂获得性耐药的机制。
Lung Cancer. 2015 Nov;90(2):364-8. doi: 10.1016/j.lungcan.2015.09.002. Epub 2015 Sep 8.
10
Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.人非小细胞肺癌中表皮生长因子受体-酪氨酸激酶抑制剂获得性耐药的当前机制及更新的治疗策略
J Cancer Res Ther. 2016 Dec;12(Supplement):C131-C137. doi: 10.4103/0973-1482.200613.

引用本文的文献

1
Case Report: Transforming small cell lung cancer: two cases report and literature review.病例报告：转化型小细胞肺癌：两例报告及文献综述
Front Oncol. 2025 Apr 3;15:1573624. doi: 10.3389/fonc.2025.1573624. eCollection 2025.
2
Patients outcomes in lung adenocarcinoma transforming to small-cell lung cancer after tyrosine kinase inhibitor therapy.酪氨酸激酶抑制剂治疗后肺腺癌转化为小细胞肺癌患者的预后
World J Surg Oncol. 2025 Feb 1;23(1):34. doi: 10.1186/s12957-025-03687-4.
3
Histological transformation in lung adenocarcinoma: Insights of mechanisms and therapeutic windows.

本文引用的文献

1
Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases.肺腺癌向小细胞肺癌转化：6例临床病理分析
J Pathol Transl Med. 2016 Jul;50(4):258-63. doi: 10.4132/jptm.2016.04.19. Epub 2016 May 10.
2
Small-Cell Lung Cancer Transformation in Patients With Pulmonary Adenocarcinoma: A Case Report and Review of Literature.肺腺癌患者发生小细胞肺癌转化：1例报告并文献复习
Medicine (Baltimore). 2016 Feb;95(6):e2752. doi: 10.1097/MD.0000000000002752.
3
Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma.
肺腺癌中的组织学转化：机制与治疗时机的见解
J Transl Int Med. 2024 Nov 6;12(5):452-465. doi: 10.1515/jtim-2024-0019. eCollection 2024 Nov.
4
Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer.癌基因依赖型非小细胞肺癌的形态-分子转化。
Int J Mol Sci. 2022 Apr 9;23(8):4164. doi: 10.3390/ijms23084164.
5
Autophagic tumor-associated macrophages promote the endothelial mesenchymal transition in lung adenocarcinomas through the FUT4/p-ezrin pathway.自噬性肿瘤相关巨噬细胞通过FUT4/磷酸化埃兹蛋白途径促进肺腺癌中的内皮-间质转化。
J Thorac Dis. 2021 Oct;13(10):5973-5985. doi: 10.21037/jtd-21-1519.
6
Clinicopathological and immunohistochemical study of pulmonary neuroendocrine tumors - A single-institute experience.肺神经内分泌肿瘤的临床病理及免疫组化研究——单中心经验
Lung India. 2021 Mar-Apr;38(2):134-138. doi: 10.4103/lungindia.lungindia_482_19.
7
Pathological transition as the arising mechanism for drug resistance in lung cancer.病理性转变作为肺癌耐药产生的机制。
Cancer Commun (Lond). 2019 Oct 1;39(1):53. doi: 10.1186/s40880-019-0402-8.
神经内分泌表型作为ALK重排肺腺癌的一种获得性耐药机制。
Lung Cancer. 2016 Feb;92:15-8. doi: 10.1016/j.lungcan.2015.12.001. Epub 2015 Dec 4.
4
Transformation to small-cell lung cancer as a mechanism of acquired resistance to crizotinib and alectinib.转化为小细胞肺癌作为对克唑替尼和阿来替尼获得性耐药的一种机制。
Jpn J Clin Oncol. 2016 Feb;46(2):170-3. doi: 10.1093/jjco/hyv173. Epub 2015 Nov 27.
5
Histological transformation from non-small cell to small cell lung carcinoma after treatment with epidermal growth factor receptor-tyrosine kinase inhibitor.表皮生长因子受体酪氨酸激酶抑制剂治疗后发生的非小细胞向小细胞肺癌的组织学转化。
Thorac Cancer. 2015 Nov;6(6):800-4. doi: 10.1111/1759-7714.12217. Epub 2014 Dec 29.
6
Transformation to large cell neuroendocrine carcinoma as acquired resistance mechanism of EGFR tyrosine kinase inhibitor.转化为大细胞神经内分泌癌作为 EGFR 酪氨酸激酶抑制剂获得性耐药的机制。
Lung Cancer. 2015 Nov;90(2):364-8. doi: 10.1016/j.lungcan.2015.09.002. Epub 2015 Sep 8.
7
Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.非小细胞肺癌向小细胞肺癌的转变：分子驱动因素及起源细胞
Lancet Oncol. 2015 Apr;16(4):e165-72. doi: 10.1016/S1470-2045(14)71180-5.
8
Small-cell carcinoma in the setting of pulmonary adenocarcinoma: new insights in the era of molecular pathology.肺腺癌中小细胞癌：分子病理时代的新认识。
J Thorac Oncol. 2013 Oct;8(10):1265-71. doi: 10.1097/JTO.0b013e3182a407fa.
9
Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.表皮生长因子受体酪氨酸激酶抑制剂治疗失败后的非小细胞肺癌治疗。
Cancer Res Treat. 2013 Jun;45(2):79-85. doi: 10.4143/crt.2013.45.2.79. Epub 2013 Jun 30.
10
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.155 例 EGFR 突变型肺癌患者获得性 EGFR-TKI 治疗耐药时的肿瘤标本分析。
Clin Cancer Res. 2013 Apr 15;19(8):2240-7. doi: 10.1158/1078-0432.CCR-12-2246. Epub 2013 Mar 7.